Concepedia

Kiana Keyvanjah

KK

Statistics

Publications

11

Citations

1.1K

H-Index

10

Active since

2012

Affiliations

Puma Biotechnology (United States)(Current)

Institut Gustave Roussy

Vall d'Hebron Institute of Oncology

Vall d'Hebron Hospital Universitari

University of Ulsan

Kiana Keyvanjah is an author at Puma Biotechnology (United States) specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2012–2024

11

Publications

11

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2020 · 609 citations · Full text

, , +15

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2019 · 100 citations

, , +16

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

Jordi Rodón, Hans Prenen, Adrian G. Sacher et al. · Annals of Oncology · 2024 · 96 citations · Full text

, , +8

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Ana Oaknin, Claire F. Friedman, Lynda D. Roman et al. · Gynecologic Oncology · 2020 · 71 citations · Full text

, , +16

AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers

Brian Belmontes, Katherine K. Slemmons, Chun Su et al. · Cancer Discovery · 2024 · 70 citations · Full text

, , +17

1–5 of 11